| Literature DB >> 27598176 |
Charlotte Falaise1, Cyrille François2, Marie-Agnès Travers3, Benjamin Morga4, Joël Haure5, Réjean Tremblay6, François Turcotte7, Pamela Pasetto8, Romain Gastineau9, Yann Hardivillier10, Vincent Leignel11, Jean-Luc Mouget12.
Abstract
The search for novel compounds of marine origin has increased in the last decades for their application in various areas such as pharmaceutical, human or animal nutrition, cosmetics or bioenergy. In this context of blue technology development, microalgae are of particular interest due to their immense biodiversity and their relatively simple growth needs. In this review, we discuss about the promising use of microalgae and microalgal compounds as sources of natural antibiotics against human pathogens but also about their potential to limit microbial infections in aquaculture. An alternative to conventional antibiotics is needed as the microbial resistance to these drugs is increasing in humans and animals. Furthermore, using natural antibiotics for livestock could meet the consumer demand to avoid chemicals in food, would support a sustainable aquaculture and present the advantage of being environmentally friendly. Using natural and renewable microalgal compounds is still in its early days, but considering the important research development and rapid improvement in culture, extraction and purification processes, the valorization of microalgae will surely extend in the future.Entities:
Keywords: Haslea; antibacterial; antifungal; antimicrobial; antiviral; biological activity; microalgae; sustainable aquaculture
Mesh:
Substances:
Year: 2016 PMID: 27598176 PMCID: PMC5039530 DOI: 10.3390/md14090159
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Antibacterial activity from microalgae against human pathogenic bacteria.
| Microalgae Species | Antibacterial Compound/Fraction | (G+) Bacteria Growth Inhibition | (G−) Bacteria Growth Inhibition | References |
|---|---|---|---|---|
| Aqueous or methanolic and exanolic extracts | [ | |||
| Ethanolic extracts | [ | |||
| Various organic solvent extracts | [ | |||
| Chlorellin | [ | |||
| Aqueous or methanolic and hexanolic extracts | [ | |||
| alpha-linolenic acid | [ | |||
| Various organic solvent extracts and purified pigments (carotenoid, chlorophyll) | [ | |||
| Ethanolic extracts | [ | |||
| Polyunsatured fatty acids: alpha-linolenic acid | [ | |||
| Indolic derivative, polyunsaturated fatty acids, beta-ionone and neophytadiene | [ | |||
| Lysed cells | [ | |||
| Short-chain fatty acids | [ | |||
| Pellet | Ne | [ | ||
| Methanolic extracts | [ | |||
| Long chain fatty acids | [ | |||
| Various organic solvent extracts | [ | |||
| Ethanolic extracts | [ | |||
| Phycobiliproteins | Nt | [ | ||
| Methanolic extracts | [ | |||
| Pellet | [ | |||
| Exopolysaccharides | Ne | [ | ||
| Whole cell | [ | |||
| Methanolic extracts | Ne | [ | ||
| Unsaturated fatty acid-containing lipidic fractions (triglycerides and docosa-pentaenoic acid (DPA)) | [ | |||
| transphytol ester, hexadecatetraenoic and octadecatetraenoic acids | [ | |||
| eicosapentaenoic acid (EPA), palmitoleic and hexadecatrienoic acids (HTA) | Ne | [ | ||
| Various organic solvent extracts | [ | |||
| Non-axenic culture and organic solvent extracts | [ | |||
| Aqueous and organic extracts | [ | |||
| Various organic solvents extracts | Ne | [ | ||
| Chlorophyll a derivatives: pheophytin a and chlorophyllide a | Nt | [ |
Ne = No effect of the microalgal compound against the bacteria tested; Nt = Not tested; MRSA = Methicillin resistant S. aureus.
Antibacterial activity from microalgae against diseases in aquaculture.
| Microalgae Species | Compound/Fraction Tested | Target Bacteria/Antibacterial Effect | References |
|---|---|---|---|
| Whole cell | [ | ||
| Aqueous extract | [ | ||
| Organic solvent extracts | [ | ||
| Purified pigment (intra- and extracellular forms) | [ | ||
| Purified marennine (intra- and extracellular forms) | [ | ||
| Purified marennine (intracellular form) | [ | ||
| Purified marennine (extracellular form) | [ | ||
| Aqueous and organic extracts | [ | ||
| Polyunsaturated free fatty acid | [ | ||
| Aqueous and Organic extracts | [ | ||
| Organic and purified extracts | [ | ||
| Aqueous extracts | [ | ||
| Microalgal homogenates | [ | ||
| Microalgal supernatant and microalgal homogenates of a commercial spray-dried preparation | [ | ||
| Axenic culture | [ | ||
| Axenic culture | [ | ||
| Axenic culture | [ | ||
| Non-axenic culture | [ | ||
| Axenic culture | [ | ||
| Axenic culture | [ | ||
| Axenic culture | [ | ||
| Exometabolites in the culture fluid | [ | ||
| Axenic culture | [ | ||
| Axenic culture | [ | ||
| 30 min incubation of enriched | Decrease of the bacterial load in | [ | |
| Daily diet of | Protection against | [ | |
| Incubation of | Higher survival and physiological conditions of larvae challenged with | [ | |
| 4 h incubation of | Diminution of associated bacteria, better bacterial diversity and the flora less dominated by | [ | |
| Food supplement for the Atlantic salmon | Reduction of | [ | |
| Food supplement for the broodstock and partial live larvae feed for the white prawn | Reduction of | [ |
Figure 1Growth inhibition of Vibrio tasmaniensis CIP 107715 by purified marennine, the blue pigment produced by Haslea ostrearia. (a) V. tasmaniensis was grown over night at 25 °C, cells were then washed with sterile water 2 times and adjusted to an OD600 = 0.5. Cells were added to wells with marennine in the following concentrations: 0, 0.1, 1, 10, 100 and 1000 μg per mL. Kinetics were run at OD600 for 48 h, with measurements taken every 30 min (n = 3); (b) Relative values were graphed in order to account for the absorbance differences due to the pigment. The effective concentration reducing bacteria growth rate by 50%, EC50, was estimated at 19.14 μg per mL (Standard error: 6.73) (original results).
Figure 2Relative growth inhibition of three Vibrio species, V. aestuarianus, V. coralliilyticus, V. tubiashii, after a 48 h exposition to purified extracellular marennine, produced by the diatom Haslea ostrearia. Each strain was grown over night in a Mueller-Hinton Broth medium at 22 °C and their concentration was then adjusted to an OD600 = 0.1. Bacterial cultures were exposed for 48 h to marennine at a concentration of 100 µg per mL before OD measurement. The relative growth inhibition was assessed in comparison with the growth of the control, not exposed to marennine. Results are means ± SD, for two separate experiments conducted using triplicates. A significant difference of sensitivity (*) between the two V. aestuarianus and V. coralliilyticus strains was observed (ANOVA statistical test, p-value 0.01 and 7 × 10−4 respectively). (original results).
Antifungal activity from microalgae.
| Microalgae Species | Antifungal Compounds/Fraction | Target Microorganims | References | |
|---|---|---|---|---|
| Microalgal supernatant | Yeast: | [ | ||
| Organic solvent extracts and pigments: beta carotene, Chlorophyll a and Chlorophyll b | Yeast: | [ | ||
| Microalgal supernatant | Yeast: | [ | ||
| Short-chain fatty acids | Yeast: | [ | ||
| Organic solvent extracts | Yeast: | [ | ||
| Phycobiliproteins | Yeast: | [ | ||
| Microalgal supernatant | Yeast: | [ | ||
| Exopolysaccharides | Yeast: | [ | ||
| Polysaccharides | Mold: | [ | ||
| Lipidic fractions: triglycerides, docosapentaenoic acid (DPA) | Yeast: | [ | ||
| Purified pigment (intra- and extracellular forms) | [ | |||
| culture filtrates and organic solvent extracts | Yeast: | [ | ||
| Polyols: karatungiols A(1) | Mold: | [ | ||
| Gambieric acids A and B forms | Mold: | [ | ||
| Goniodomin A (polyether macrolide) | Yeast: | [ | ||
| Polyethers | Yeast: | [ | ||
Antiviral activity from microalgae.
| Microalgae Species | Antiviral Compound and Cytotoxicity (μg/mL) | Target Virus | Mechanism of Action and Efficiency (μg/mL) | References |
|---|---|---|---|---|
| Polysaccharide-rich fraction CC50 > 1600 (Vero cells) | HSV-1 | Inhibits attachment, replication | [ | |
| IC50 = 61 | ||||
| Pheophorbide-like compound Not cytotoxic (Vero cells) | HSV-1 | Inhibits adsorption, invasion | [ | |
| MIC = 5 (totally inhibit the CPE) | ||||
| Short chain fatty acids, β-ionone, neophytadiene, phytol, palmitic and α-linolenic acids CC50 = 1711 (Vero cells) | HSV-1 | Inhibits infectivity | [ | |
| IC50 = 85 | ||||
| Polysaccharide-rich fraction CC50 = 1867 (Vero cells) | HSV-1 | Inhibits attachment, penetration, replication | [ | |
| IC50 = 99 | ||||
| Sulphated exopolysaccharide Not cytotoxic at 100 (HeL cells) | Inhibits penetration, replication | [ | ||
| HSV-1 | EC50 (HSV-1) = 34 | |||
| HSV-2 | EC50 (HSV-2) = 12 | |||
| Vaccina | EC50 (Vaccina) = 12 | |||
| Exopolysaccharide Not cytotoxic at 500 (HEp-2 cells) | Vaccina | Interaction with free viral particles | [ | |
| IC50 = 0.65 | ||||
| Sulphated polysaccharide Not cytotoxic at 250 (Vero cells) and 2000 (in vivo in rats) | HSV-1 | In vitro: inhibits adsorption, replication | [ | |
| CPE50 = 1 | ||||
| In vivo: prevents the development of symptoms at 100 | ||||
| Inhibits adsorption, replication | ||||
| HSV-2 | CPE50 (HSV-2) = 5 | |||
| VZV | CPE50 (VZV) = 0.7 | |||
| Purified polysaccharide Not cytotoxic at 1000 (NIH/3T3 cells) | MuSV/MuLV | Inhibits the production of retroviruses in the cells | [ | |
| RT50 reduction = 5 | ||||
| MuSV-124 | Inhibits cell transformation | |||
| ffu50 protection = 10 | ||||
| Purified pigment: intra- and extracellular forms | HSV-1 | Inhibits infection, cell destruction | [ | |
| CC50 (Int) = 87 | EC50 (Int) = 62 | |||
| CC50(Ext) > 200 (Vero cells) | EC50 (Ext) = 23 | |||
| Purified pigment: intra- and extracellular forms | HSV-1 | Inhibits infection, cell destruction | [ | |
| CC50 (Int) > 200 (Vero cells) | EC50 (Int) = 24 | |||
| CC50 (Ext) = 107 (Vero cells) | EC50 (Ext) = 27 | |||
| Water soluble extract CC50 > 200 (Vero and MT-4 cells) | HSV-1 | Inhibits replication | [ | |
| EC50 = 14 | ||||
| Sulphated polysaccharide: Naviculan | Inhibits adhesion, penetration | [ | ||
| CC50 (HSV-1) = 3800 (Vero cells) | HSV-1 | IC50 (HSV-1) = 14 | ||
| CC50 (HSV-2) = 3800 (Vero cells) | HSV-2 | IC50 (HSV-2) = 7.4 | ||
| CC50 (IFV-A)= 5400 (MDCK cells) | IFV-A | IC50 (IFV-A) = 170 | ||
| CC50 (HIV-1) = 4000 (HeLA cells) | HIV-1 | IC50 (HIV-1) = 53 | ||
| Extracellular sulphated polysaccharides: A1 and A2 | Inhibits replication and the CPE | [ | ||
| CC50 (HIV-1) > 100 (MT-4 cells) | HIV-1 | IC50 (HIV-1) = 1.7 | ||
| CC50 (IFV-A) > 100 (MDCK cells) | IFV-A | IC50 (IFV-A) = 0.45–1 | ||
| CC50 (IFV-B) > 100 (MDCK cells) | IFV-B | IC50 (IFV-B) = 7.1–8.3 | ||
| CC50 (RSV-A) > 100 (Hep-2 cells) | RSV-A | IC50 (RSV-A) = 2–3 | ||
| CC50 (RSV-B) > 100 (Hep-2 cells) | RSV-B | IC50 (RSV-B) = 0.8 | ||
| A1 | HSV-1 | IC50 = 4.5 | ||
| CC50 > 100 (HMV-2 cells) | ||||
| A2 | PFluV-2 | IC50 = 0.8 | ||
| CC50 > 100 (HMV-2 cells) | ||||
| Purified sulphated exopolysaccharide: p-KG03 | EMCV | Inhibits the development of the CPE, suppress tumor cell growth EC50 = 27 | [ | |
| CC50 = 3.4 (MT-4 cells) | ||||
| CC50 = 59.9 (Vero cells) | ||||
| CC50 > 1000 (HeLa cells) | ||||
| Not in MDCK cells CC50 > 100 | Inhibits adsorption | [ | ||
| IFV-A | EC50 (IFV-A) = 0.19–0.48 | |||
| IFV-B | EC50 (IFV-B) = 0.26 |
EMCV: encephalomyocarditis virus; HIV-1: human immunodeficiency virus type 1; HSV-1: Herpes simplex virus type 1; HSV-2: herpes simplex virus type 2; IFV-A: influenza A virus; IFV-B: influenza B virus; MuLV: murine leukemia virus; MuSV-124: murine sarcoma virus; RSV: respiratory syncytial virus; VZV: varicella zoster virus. CC50: concentration that kills 50% of the infected cells; CPE50: concentration that offers 50% protection against the cytopathic effect; EC50: concentration requires to inhibit 50% of the virus-induced cytopathic effects (CPE); ffu50: concentration that offers 50% protection against the formation of foci of malignant cells; IC50: concentration that inhibits 50% of the virus infection; MIC: minimum inhibitory concentration; RT50: concentration that offers 50% reduction of reverse transcriptase activity.